Bob Terbrueggen, Ph.D., is the Founder and CEO of DxTerity Diagnostics, a molecular diagnostics company based in Los Angeles, California, USA. DxTerity specializes in the development of low cost, high throughput genomic tests. In September 2016, DxTerity was awarded a multi-year, $150 million contract by the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the Advanced Development and Delivery of its REDI-Dx® High Throughput Radiation Biodosimetry Test.
Prior to founding DxTerity, Bob was Director of Research and Development for Clinical Micro Sensors (CMS) and Motorola Life Sciences. Bob received his Ph.D. in Chemistry from the California Institute of Technology (CalTech), and his BS in Chemistry and Molecular Biology for the University of Michigan. Bob is an inventor on 20 approved U.S. patents and more than 20 pending applications.